Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 55 for:    linolenic acid

ALA on Glycemic Control in T2DM Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02701894
Recruitment Status : Unknown
Verified March 2016 by Vladimir Vuksan, St. Michael's Hospital, Toronto.
Recruitment status was:  Active, not recruiting
First Posted : March 8, 2016
Last Update Posted : March 8, 2016
Sponsor:
Information provided by (Responsible Party):
Vladimir Vuksan, St. Michael's Hospital, Toronto

Brief Summary:
With the emerging worldwide epidemic of type 2 diabetes, dietary recommendations to improve diabetes management have been emphasized in the scientific community. Particular attention has been drawn to various benefits of replacing saturated fatty acids with unsaturated fatty acids. Alpha-linolenic acid, the only omega-3 fatty acid that is from plant sources, has been suggested by animal and cell studies to play a beneficial role in regulating blood glucose levels. However, human studies have been more inconsistent with their findings. The focus of this project is to investigate the evidence in the context of ALA and blood glucose parameters in participants with type 2 diabetes by conducting a systematic review and meta-analysis of randomized controlled trials.

Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Dietary Supplement: Alpha-Linolenic Acid

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Time Perspective: Retrospective
Official Title: The Effect of Alpha-Linolenic Acid on Glycemic Control in Participants With Type 2 Diabetes
Study Start Date : December 2012
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : March 2016

Resource links provided by the National Library of Medicine



Intervention Details:
  • Dietary Supplement: Alpha-Linolenic Acid
    Meta-Analysis of Randomized Controlled Trials
    Other Name: ALA


Primary Outcome Measures :
  1. HbA1c [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Fructosamine [ Time Frame: 1 month ]
  2. Fasting Blood Glucose [ Time Frame: 1 month ]
  3. Fasting Blood Insulin [ Time Frame: 1 month ]
  4. Glycated Albumin [ Time Frame: 1 month ]
  5. HOMA- IR [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants with type 2 diabetes mellitus.
Criteria

Inclusion Criteria:

  • Controlled, randomized, clinical trials
  • Trials greater than one month
  • Focusing on ALA and T2DM participants
  • Viable endpoint data

Exclusion Criteria:

  • Non-human studies
  • Non-random treatment allocation
  • Less than 1 month
  • Lack of suitable control
  • Lack of endpoint data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02701894


Sponsors and Collaborators
St. Michael's Hospital, Toronto
Investigators
Layout table for investigator information
Principal Investigator: Vladimir Vuksan, PhD St. Michael's Hospital, Toronto

Layout table for additonal information
Responsible Party: Vladimir Vuksan, Research Scientist & Professor, St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier: NCT02701894     History of Changes
Other Study ID Numbers: ALA and GC in T2D
First Posted: March 8, 2016    Key Record Dates
Last Update Posted: March 8, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases